Last reviewed · How we verify
Olanzapine-Fluoxetine Combination
Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects.
Olanzapine blocks dopamine and serotonin receptors while fluoxetine inhibits serotonin reuptake, together providing antipsychotic and antidepressant effects. Used for Bipolar I disorder depression, Treatment-resistant depression with psychotic features.
At a glance
| Generic name | Olanzapine-Fluoxetine Combination |
|---|---|
| Also known as | Oleanz Fort, Oleanz Plus |
| Sponsor | All India Institute of Medical Sciences, Bhubaneswar |
| Drug class | Atypical antipsychotic + SSRI combination |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor, serotonin transporter (SERT) |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Olanzapine is an atypical antipsychotic that antagonizes dopamine D2 and serotonin 5-HT2A receptors, reducing psychotic symptoms. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that increases synaptic serotonin by blocking its reuptake. The combination targets both dopaminergic and serotonergic pathways to address psychotic and depressive symptoms simultaneously.
Approved indications
- Bipolar I disorder depression
- Treatment-resistant depression with psychotic features
Common side effects
- Weight gain
- Sedation
- Nausea
- Akathisia
- Sexual dysfunction
- Metabolic syndrome
Key clinical trials
- Low Dose Amisulpride Vs Olanzapine-Fluoxetine Combination in Post-Schizophrenic Depression (PHASE4)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (PHASE4)
- Treatment of Hypochondriasis With CBT and/or SSRI (PHASE1, PHASE2)
- Olanzapine in Patients With Advanced Cancer and Weight Loss (PHASE1)
- A Study in Relapse Prevention of Treatment-Resistant Depression (PHASE3)
- Treatment of Obsessive-Compulsive Disorder (PHASE4)
- A Study for Assessing Treatment of Patients Ages 10-17 With Bipolar Depression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: